Brokerages Expect Corium International, Inc. (CORI) to Announce -$0.42 EPS
Analysts predict that Corium International, Inc. (NASDAQ:CORI) will announce earnings per share of ($0.42) for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Corium International’s earnings, with the highest EPS estimate coming in at ($0.40) and the lowest estimate coming in at ($0.44). Corium International reported earnings per share of ($0.46) in the same quarter last year, which suggests a positive year over year growth rate of 8.7%. The company is scheduled to issue its next quarterly earnings results on Monday, February 12th.
According to Zacks, analysts expect that Corium International will report full year earnings of ($1.47) per share for the current financial year, with EPS estimates ranging from ($1.52) to ($1.40). For the next fiscal year, analysts forecast that the business will report earnings of ($1.42) per share, with EPS estimates ranging from ($1.60) to ($1.23). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Corium International.
A number of research analysts recently issued reports on CORI shares. HC Wainwright set a $15.00 price objective on shares of Corium International and gave the company a “buy” rating in a research note on Friday, November 17th. Jefferies Group reissued a “buy” rating and issued a $10.00 price objective (up from $8.00) on shares of Corium International in a research note on Monday, August 7th. BidaskClub raised shares of Corium International from a “sell” rating to a “hold” rating in a research note on Friday, August 25th. ValuEngine raised shares of Corium International from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $12.00 price objective on shares of Corium International in a research note on Wednesday, September 27th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $13.00.
In other Corium International news, major shareholder Healthcare Master Fun Broadfin sold 218,100 shares of the firm’s stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $11.01, for a total value of $2,401,281.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders sold 868,100 shares of company stock worth $9,538,781 in the last 90 days. Company insiders own 45.70% of the company’s stock.
A number of institutional investors have recently modified their holdings of CORI. Bank of New York Mellon Corp lifted its holdings in shares of Corium International by 118.1% during the first quarter. Bank of New York Mellon Corp now owns 25,269 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 13,683 shares during the period. Teachers Advisors LLC acquired a new position in shares of Corium International during the second quarter worth $272,000. TIAA CREF Investment Management LLC acquired a new position in shares of Corium International during the second quarter worth $411,000. New York State Common Retirement Fund acquired a new position in shares of Corium International during the second quarter worth $158,000. Finally, EAM Investors LLC acquired a new position in shares of Corium International during the second quarter worth $563,000. Hedge funds and other institutional investors own 89.35% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/11/30/brokerages-expect-corium-international-inc-cori-to-announce-0-42-eps.html.
Corium International Company Profile
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.